Glymera
AssetAlso called PB1023, PF-1801
Long-acting GLP-1 receptor agonist fusion protein that stimulates glucose-dependent insulin secretion and improves glycemic control.
- Stage
- Phase 2, no development reported
- Modality
- Protein or enzyme
- Target
- Not known
- 1
- Indication
- 2
- Trials
- 1
- Developer
No development reported since July 2013. Last activity: Trial NCT01658501 completed. clinicaltrials.gov
Indications
1Type 2 diabetes
Phase 2, Completed, NCT01658501, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials2
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.